AstraZeneca
- The drugmaker’s shares fell by as much as 8 percent earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01
- The company said on Friday it will continue with its plan to file data from the trial with FDA
© 2024 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement.